{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:35:16Z","timestamp":1790886916316,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4662,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1093\/annonc\/mdl427","type":"journal-article","created":{"date-parts":[[2006,12,9]],"date-time":"2006-12-09T02:05:33Z","timestamp":1165629933000},"page":"498-503","source":"Crossref","is-referenced-by-count":37,"title":["FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Ent\u00e9rologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study"],"prefix":"10.1016","volume":"18","author":[{"given":"J.","family":"Ta\u00efeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Asnacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mansourbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Artru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fallik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Desrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl427_bb0010","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0959-8049(98)00330-X","article-title":"Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. EUROCARE Working Group","volume":"34","author":"Faivre","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdl427_bb0015","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ijc.2910570605","article-title":"Trends in pancreatic cancer mortality in Europe, 1955 \u20131989","volume":"57","author":"Fernandez","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdl427_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bpg.2005.10.001","article-title":"Epidemiology and risk factors for pancreatic cancer","volume":"20","author":"Lowenfels","year":"2006","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1093\/annonc\/mdl427_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/oxfordjournals.annonc.a059031","article-title":"Pancreatic carcinoma","volume":"6","author":"Kelly","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0030","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0035","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0040","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297","volume":"20","author":"Berlin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjc.6600446","article-title":"A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer","volume":"87","author":"Bramhall","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdl427_bb0050","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.10323","article-title":"Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and\/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale","volume":"94","author":"Colucci","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdl427_bb0055","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdi309","article-title":"A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer","volume":"16","author":"Oettle","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00001813-199506000-00008","article-title":"Cytotoxicity of CPT-11 for gastrointestinal cancer cells cultured on fixed-contact-sensitive plates","volume":"6","author":"Matsuoka","year":"1995","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdl427_bb0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00001813-199606000-00010","article-title":"Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice","volume":"7","author":"Bissery","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdl427_bb0070","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0006-291X(92)90634-W","article-title":"Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA\/PCR-based quantitation assay","volume":"184","author":"Takeda","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdl427_bb0075","first-page":"1039","article-title":"A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer","volume":"21","author":"Sakata","year":"1994","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1093\/annonc\/mdl427_bb0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/oxfordjournals.annonc.a059107","article-title":"Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study","volume":"6","author":"Wagener","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0085","first-page":"5209","article-title":"Irinotecan(Campto R): efficacy as third\/fourth line therapy in advanced pancreatic cancer","volume":"20","author":"Klapdor","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdl427_bb0090","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/sj.bjc.6600883","article-title":"Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma","volume":"88","author":"Ulrich-Pur","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdl427_bb0095","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<729::AID-IJC20>3.0.CO;2-#","article-title":"Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo","volume":"73","author":"Guichard","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdl427_bb0100","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0959-8049(99)00222-1","article-title":"Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines","volume":"35","author":"Mans","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdl427_bb0105","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s002800050835","article-title":"Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity","volume":"42","author":"Mullany","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdl427_bb0110","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.2001.19.15.3456","article-title":"Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients","volume":"19","author":"Falcone","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.COC.0000020581.59835.7A","article-title":"Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer","volume":"26","author":"Mabro","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0120","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/sj.bjc.6603095","article-title":"A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients","volume":"94","author":"Mabro","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdl427_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdl427_bb0130","first-page":"1079","article-title":"How large should a phase II trial of a new drug be?","volume":"71","author":"Simon","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/annonc\/mdl427_bb0135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/978-3-642-19022-3_15","article-title":"Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer","volume":"161","author":"Kornmann","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"10.1093\/annonc\/mdl427_bb0140","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1073\/pnas.92.17.7690","article-title":"Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein","volume":"92","author":"Zaman","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdl427_bb0145","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0150","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/oxfordjournals.annonc.a058495","article-title":"Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma","volume":"4","author":"Rougier","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0155","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1023\/A:1026595525977","article-title":"Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer","volume":"11","author":"Heinemann","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0160","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.2004.12.082","article-title":"Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate","volume":"22","author":"Rocha Lima","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0165","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/annonc\/mdg029","article-title":"Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0175","first-page":"1003","article-title":"A phase III trial comparing gemcitabine plus cisplatin versus gemcitabine alone in advanced pancreatic carcinoma","volume":"21","author":"Heinemann","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0180","first-page":"PS11","article-title":"Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"4","author":"Cunningham","year":"2005","journal-title":"Eur J Can"},{"key":"10.1093\/annonc\/mdl427_bb0185","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2005.01.9661","article-title":"Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer","volume":"23","author":"Kindler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0190","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2004.12.040","article-title":"Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial","volume":"22","author":"Xiong","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0195","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","article-title":"Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer\u2014a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study","volume":"23","author":"Conroy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0200","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1634\/theoncologist.6-6-488","article-title":"Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer","volume":"6","author":"Kozuch","year":"2001","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdl427_bb0205","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2002.20.5.1182","article-title":"Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer","volume":"20","author":"Rocha Lima","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0210","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/annonc\/mdg109","article-title":"Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer","volume":"14","author":"Stathopoulos","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl427_bb0215","first-page":"841","article-title":"Sequential polychemotherapy in exocrine pancreatic cancer","volume":"23","author":"Klapdor","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdl427_bb0220","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00001813-200011000-00001","article-title":"The role of gemcitabine alone and in combination in the treatment of pancreatic cancer","volume":"11","author":"Oettle","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdl427_bb0225","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10637-005-1446-y","article-title":"Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study","volume":"23","author":"Tsavaris","year":"2005","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdl427_bb0230","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2002.09.029","article-title":"Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer","volume":"20","author":"Maisey","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419378329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419378329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/3\/498\/1349482\/mdl427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T18:10:07Z","timestamp":1635790207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419378329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0923753419378329"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl427","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}